Valuing wellness, IV, and hormone services inside a med spa: isolate the business economics

Value wellness, IV, and hormone services as distinct operating lines before combining them with aesthetics earnings. Verify earned revenue, direct and shared costs, prescribing and clinical arrangements, product sourcing, patient continuity, and transferability. Recurring billing alone does not establish durable profit. A buyer needs a supportable operating case for the services it can lawfully continue.

Why should wellness revenue be analyzed separately?

An aesthetics practice can report one revenue total while operating several different businesses inside it. IV visits, hormone consultations, laboratory coordination, product dispensing, subscriptions, and injectable aesthetics may use different professionals, inventory, scheduling, and clinical processes. Blending them can conceal both profitable services and unsupported assumptions.

Service-line contribution is revenue on a defined basis less the costs assigned under a stated methodology to that service. It is an analytical subtotal rather than a universal accounting standard. Explain direct costs, allocated shared costs, and costs excluded from the calculation before comparing different lines.

Begin with a service map showing what the patient buys, who provides or prescribes it, who bills, who owns the inventory, and which entity receives cash. Product names and wellness branding do not answer those questions. The map should reconcile to actual transactions and contracts rather than only the published menu.

What should the revenue reconciliation show?

Distinguish consultations, visits, memberships, medicines, laboratory charges, retail products, and third-party collections. Identify refunds, discounts, failed payments, credits, and outstanding benefits. Determine whether the practice is presenting its own revenue or passing through amounts earned by another provider or supplier.

IRS recordkeeping guidance identifies transaction support as a foundation for business records. For valuation, connect source records to the service ledger, general ledger, tax reporting, merchant activity, and bank deposits. Explain differences in timing or presentation rather than assuming cash receipts prove earned revenue.

Review periods before and after any material program launch or change. Growth driven by a temporary promotion, new prescriber, or newly added product may have a different evidence base from a mature line. Show the available history and the limits of annualizing a short period.

Which clinical and legal dependencies require review?

Have qualified advisors identify applicable rules for ownership, prescribing, evaluation, professional scope, delegation, supervision, dispensing, laboratory arrangements, and telehealth. These depend on the service, profession, jurisdiction, and facts. A medical director contract or common industry practice is not sufficient evidence that every activity is permitted.

The Medical Board of California’s medical-spa guidance illustrates why cosmetic medical services require a properly structured clinical operation in that state. Its rules should not be generalized to every wellness line or every state. Obtain specific review of the services and professionals involved in the proposed transaction.

Document the current professionals, agreements, protocols, licenses, coverage, and responsible entities. Ask what changes when ownership or a key provider changes. If an important line depends on a professional who will not remain, model the replacement arrangement and the transition before assuming revenue continues uninterrupted.

How should compounded products and sourcing be assessed?

FDA’s explanation of compounded-drug risks states that compounded drugs are not FDA approved and that the agency does not review their safety, effectiveness, or quality before marketing. This does not establish that every compounded product is unlawful; it establishes a need for accurate claims and product-specific review.

Inventory the actual products and sources rather than treating IV or hormone therapy as one category. Request purchase records, supplier identity, applicable registrations or licenses, product information, storage procedures, recall handling, and adverse-event processes. Have the appropriate professionals review the federal and state requirements relevant to each arrangement.

Do not value a line on assumptions that a product will always remain available on the same terms. Supply, lawful compounding conditions, prescribing arrangements, or marketing restrictions can change. Record dependencies and model a compliant alternative or interruption with qualified input instead of promising clinical substitutions.

Which costs are easily missed in a promising revenue line?

Include professional evaluation and follow-up, clinical staffing, product, consumables, laboratory coordination, waste, insurance, training, software, payment processing, and administrative support. Review which costs are fixed, variable, shared, or triggered by volume. A product-cost-only margin can overstate the contribution available to support the business.

Reconcile allocations to the full practice P&L so that costs do not disappear between service lines. An apparently weak line may use capacity efficiently, while an apparently strong one may absorb substantial unallocated professional time. Preserve the assumptions and test a reasonable alternative allocation.

How do subscriptions affect the earnings picture?

Identify exactly what the fee buys and when the practice satisfies its obligations. A recurring charge may fund access, consultation, product, future treatments, or a bundle. Track active members, collections, delivery, unused benefits, cancellations, and refunds using consistent definitions.

An initial enrollment surge can produce cash before the associated cost of service. Review earned revenue and future obligations with the accountant. Do not add membership cash to treatment revenue if the same economic activity is already recognized elsewhere, and do not assume unused benefits are available profit.

Evaluate retention with cohorts rather than a single current member total. Separate people enrolled long enough to observe from recent sign-ups. Explain failed payments and pauses. A buyer needs to understand the relationship patients retain and the resources required to serve them responsibly.

What would an illustrative operating bridge look like?

Suppose an invented wellness line reports $300,000 of annual revenue. Product and consumables cost $90,000; professional and clinical labor costs $100,000; program-specific overhead is $25,000; and a supportable shared allocation is $35,000. The resulting contribution after those costs is $50,000.

If the buyer needs another $20,000 of annual resources to continue the line, that case falls to $30,000 before any other omitted costs. These assumptions are teaching figures, not market margins, pay benchmarks, or a valuation conclusion. Actual costs and lawful staffing must come from the practice and its advisors.

The example shows why a percentage of revenue can mislead. It also shows why removing a line is not automatically the answer: determine which shared costs would remain and whether patients use other services. Model the business with and without the line using consistent assumptions.

How should this analysis influence the transaction?

Decide whether the buyer intends to retain, modify, or discontinue each line. Identify required consents, provider continuity, product access, patient communication, record responsibilities, and transitional spending. Reflect unresolved dependencies in diligence priorities and transaction terms with counsel rather than inventing an unsupported discount percentage.

1. Map the actual services and responsible entities.
2. Reconcile revenue and outstanding promises.
3. Test full resource requirements.
4. Review legal, clinical, and sourcing dependencies.
5. Model continuity and interruption cases.
6. Use the supportable case in overall value analysis.

Continue with the valuation hub, P&L guide, product-sourcing diligence guide, and Transferability Stack. A valuable wellness line has more than an appealing growth story: its earnings, obligations, professional resources, and continuity can be explained with evidence.

What should remain outside a financial conclusion?

An earnings review does not determine whether a treatment is appropriate for an individual patient or establish efficacy for advertised claims. Keep those questions with qualified clinical professionals and legal reviewers. The transaction analysis should use their findings to understand resource needs, permitted operations, and material uncertainties.

Record which issues have been resolved, which require additional evidence, and which the buyer cannot responsibly underwrite yet. This is more useful than describing the entire line as either safe recurring revenue or uninvestable risk. Clear scope lets the parties make a decision about the actual operation being transferred.

Educational analysis prepared with AI-assisted research for The Med Spa Broker. “Last reviewed” records the source and editorial check date; it does not imply review by an attorney, clinician, or independent appraiser. Read our editorial standards.